Pharmaron Beijing Future Growth
Future criteria checks 1/6
Pharmaron Beijing is forecast to grow earnings and revenue by 6.4% and 13.6% per annum respectively. EPS is expected to grow by 6% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
6.4%
Earnings growth rate
6.0%
EPS growth rate
| Life Sciences earnings growth | 32.9% |
| Revenue growth rate | 13.6% |
| Future return on equity | 12.7% |
| Analyst coverage | Good |
| Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15,999 | 2,159 | 2,034 | 3,015 | 13 |
| 12/31/2025 | 14,081 | 1,958 | 1,758 | 2,719 | 15 |
| 12/31/2024 | 12,342 | 1,844 | N/A | 2,338 | 14 |
| 9/30/2024 | 11,795 | 1,884 | 371 | 2,495 | N/A |
| 6/30/2024 | 11,502 | 1,928 | 258 | 2,573 | N/A |
| 3/31/2024 | 11,485 | 1,483 | 390 | 2,969 | N/A |
| 12/31/2023 | 11,538 | 1,601 | -112 | 2,754 | N/A |
| 9/30/2023 | 11,424 | 1,553 | -214 | 2,777 | N/A |
| 6/30/2023 | 11,272 | 1,575 | -572 | 2,564 | N/A |
| 3/31/2023 | 10,887 | 1,474 | -806 | 2,255 | N/A |
| 1/1/2023 | 10,266 | 1,375 | -807 | 2,143 | N/A |
| 9/30/2022 | 9,545 | 1,582 | -707 | 2,037 | N/A |
| 6/30/2022 | 8,793 | 1,682 | -300 | 2,072 | N/A |
| 3/31/2022 | 8,057 | 1,664 | -242 | 1,977 | N/A |
| 12/31/2021 | 7,444 | 1,661 | -35 | 2,058 | N/A |
| 9/30/2021 | 6,849 | 1,423 | -152 | 1,905 | N/A |
| 6/30/2021 | 6,226 | 1,258 | -79 | 1,876 | N/A |
| 3/31/2021 | 5,664 | 1,317 | 125 | 1,822 | N/A |
| 12/31/2020 | 5,134 | 1,172 | 333 | 1,649 | N/A |
| 9/30/2020 | 4,717 | 1,008 | 532 | 1,565 | N/A |
| 6/30/2020 | 4,314 | 865 | 440 | 1,283 | N/A |
| 3/31/2020 | 3,953 | 594 | 370 | 1,124 | N/A |
| 12/31/2019 | 3,757 | 547 | 184 | 939 | N/A |
| 9/30/2019 | 3,499 | 437 | 146 | 837 | N/A |
| 6/30/2019 | 3,274 | 378 | 247 | 906 | N/A |
| 3/31/2019 | 3,089 | 346 | 230 | 861 | N/A |
| 12/31/2018 | 2,908 | 333 | 150 | 791 | N/A |
| 9/30/2018 | 2,713 | 300 | -721 | 692 | N/A |
| 12/31/2017 | 2,294 | 231 | N/A | 552 | N/A |
| 12/31/2016 | 1,634 | 177 | N/A | 236 | N/A |
| 12/31/2015 | 1,128 | 74 | N/A | 217 | N/A |
| 12/31/2014 | 790 | 21 | N/A | 12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300759's forecast earnings growth (6.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 300759's earnings (6.4% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 300759's earnings are forecast to grow, but not significantly.
Revenue vs Market: 300759's revenue (13.6% per year) is forecast to grow slower than the CN market (13.8% per year).
High Growth Revenue: 300759's revenue (13.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300759's Return on Equity is forecast to be low in 3 years time (12.7%).